ReviewAmerican journal of clinical dermatology2020
Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.
Review in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Molecular Characteristics of Sweet Syndrome: A Systematic Review.Experimental dermatology · 2024Pooled it
- S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV).Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Guideline
- Article
- Single-cell sequencing reveals dynamic immune features of paraneoplastic pemphigus in a patient with follicular lymphoma.Frontiers in immunology · 2026Article
- Diagnostic approach to leukemia cutis : A differential diagnostic step-by-step algorithm.American journal of clinical pathology · 2025Review
- Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.Journal of clinical medicine · 2025Review
- Concurrent presentation of acute lymphoblastic leukemia and bullous pemphigoid: a rare case report.Oxford medical case reports · 2025Article
- Sweet's syndrome with Koebner phenomenon triggered by G-CSF as a preleukemic manifestation in a patient with primary myelofibrosis: a case report.Frontiers in medicine · 2025Article
- Dermatologic manifestations of hematologic disorders.Annals of hematology · 2024Review
- Assessment of Seasonality in Eosinophilic Dermatosis of Haematological Malignancy.Acta dermato-venereologica · 2024Article
- Hematological malignancy-associated pyoderma gangrenosum: evaluating the magnitude of the association.Frontiers in medicine · 2024Article
- Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.Frontiers in immunology · 2023Review
- Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study.Frontiers in medicine · 2023Article
- Neutrophilic and eosinophilic dermatoses associated with hematological malignancy.Frontiers in medicine · 2023Review
- Cutaneous sarcoid-like reaction in a patient treated with target therapy for metastatic melanoma: the hue is the clue.Dermatologic therapy · 2022Article
- CD30+ Transformed Mycosis Fungoides Associated with Sweet-like Dermatosis.Acta dermato-venereologica · 2022Article
- Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study.Frontiers in immunology · 2022Article
- The impact on the scientific community of the 2018 addendum to the CHCC.Frontiers in medicine · 2022Article
- Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?Frontiers in immunology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological malignancies, run a benign clinical course but portend a significant negative impairment on a patient's quality of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haematological malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date overview on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, discussing new pathogenic advances and therapeutic options on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.